242 related articles for article (PubMed ID: 8643604)
1. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
[TBL] [Abstract][Full Text] [Related]
2. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
[TBL] [Abstract][Full Text] [Related]
4. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
Calderón EJ; Torres Y; Medrano FJ; Luque F; Larder B; Rey C; Sánchez-Quijano A; Lissen E; Leal M
Eur J Clin Microbiol Infect Dis; 1995 Jun; 14(6):512-9. PubMed ID: 7588824
[TBL] [Abstract][Full Text] [Related]
5. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT
J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636
[TBL] [Abstract][Full Text] [Related]
6. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
Conlon CP; Klenerman P; Edwards A; Larder BA; Phillips RE
J Infect Dis; 1994 Feb; 169(2):411-5. PubMed ID: 7508970
[TBL] [Abstract][Full Text] [Related]
7. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
[TBL] [Abstract][Full Text] [Related]
8. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
[TBL] [Abstract][Full Text] [Related]
10. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
[TBL] [Abstract][Full Text] [Related]
11. Influence of L-lysine amino acid on the HIV-1 RNA replication in vitro.
Butorov EV
Antivir Chem Chemother; 2015 Feb; 24(1):39-46. PubMed ID: 26149265
[TBL] [Abstract][Full Text] [Related]
12. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
[TBL] [Abstract][Full Text] [Related]
14. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
Cleland A; Watson HG; Robertson P; Ludlam CA; Brown AJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):6-18. PubMed ID: 8624762
[TBL] [Abstract][Full Text] [Related]
15. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
Kellam P; Boucher CA; Larder BA
Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1934-8. PubMed ID: 1371886
[TBL] [Abstract][Full Text] [Related]
16. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
17. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
[TBL] [Abstract][Full Text] [Related]
18. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.
Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Merigan TC
J Infect Dis; 1993 Mar; 167(3):526-32. PubMed ID: 7680058
[TBL] [Abstract][Full Text] [Related]
19. Early identification of human immunodeficiency virus-infected asymptomatic subjects susceptible to zidovudine by quantitative viral coculture and reverse transcription-linked polymerase chain reaction.
Lu W; Andrieu JM
J Infect Dis; 1993 May; 167(5):1014-20. PubMed ID: 7683705
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
